REG - Oxford Biomedica PLC - Notice of Preliminary Results

Oxford BioMedicaAnnouncement

15/03/2021 10:05

RNS Number : 2548S
  
Oxford Biomedica PLC
  
15 March 2021
  
 

 
 
Notice of Preliminary Results
 
 
          
Oxford, UK - 15 March 2021: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, will be announcing its preliminary results for the twelve months ended 31 December 2020 on Thursday 15 April 2021.
 
A virtual briefing and Q&A session for analysts will be held at 13.00 BST / 08.00 EST on the day of results, and the presentation and webcast details will be made available on the Group's website at www.oxb.com. A replay webcast will be made available shortly afterwards. 
 
 
-Ends-



Enquiries:








 
Oxford Biomedica plc 
 
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Catherine Isted, Head of Corporate Development & IR
 


 
 
 
T: +44 (0)1865 783 000
T: +44 (0)1865 783 000
T: +44 (0)1865 954 161 / E: ir@oxb.com
 




 
Consilium Strategic Communications 
 
Mary-Jane Elliott / Matthew Neal 


 
 
 
T: +44 (0)20 3709 5700 / 
 



 
About Oxford Biomedica
 
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NOREAEDSFEEFEFA